---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016899"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:12:27.155758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Olema Pharma Q3 net loss $22.7M; cash $222.6M; OP-1250 shows 41% tumor reduction

## Summary
- Net loss $22.7M in Q3 2022 vs $17.7M in Q3 2021; R&D expenses $17.6M GAAP ($14.8M non-GAAP).
- Cash, equivalents and marketable securities $222.6M at Sept 30, 2022; sufficient into H2 2024.
- OP-1250 monotherapy: 41% of heavily pre-treated patients had tumor reduction; 6 partial responses; Phase 2 fully enrolled.
- OP-1250 + palbociclib combo: dose escalation completed, Phase 2 expansion ongoing; no dose-limiting toxicities.
- Phase 3 monotherapy study planned for mid-2023; FDA Fast Track granted for ER+/HER2- metastatic breast cancer.

## SEC filing metadata
- accession: 0001558370-22-016899
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/0001558370-22-016899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/olma-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016899
- JSON: https://secwatch.observer/filing/0001558370-22-016899.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016899.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $22.7 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $22.7 million
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2022, was $22.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837022016899/0001558370-22-016899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.